Symbiosis Pharmaceutical Expanded Global Sales Team
The firm added five commercial roles to support international growth in Asia-Pacific, the Middle East, and Southern Europe.
Updated on Oct. 5, 2026 in Healthcare
Live Poll
Do you believe the expansion of pharmaceutical manufacturing capacity is generally good for healthcare access?
Symbiosis Pharmaceutical Services has hired five members to its commercial team to drive growth in international markets. This expansion follows the company’s recent £26 million investment to increase its aseptic manufacturing capacity for biologic and injectable therapies.
Why it matters
The appointments support the company's efforts to capitalize on rising demand for specialized drug manufacturing. By regionalizing its business development presence, the firm seeks to better manage client inquiries and secure supply contracts across three major global regions.
Symbiosis Pharmaceutical Services recently finalized a £26 million facility upgrade, which boosted its aseptic production capacity. The firm also added five commercial staff members, including hires with 15 and 10 years of industry experience, to support its global growth strategy.
The players
Symbiosis Pharmaceutical Services
A UK-based contract development and manufacturing organization specializing in sterile biologics and injectable drug products.
Jay Chima
The new vice president of business development tasked with leading the firm's commercial expansion efforts.
Jos Vergeest
The newly appointed senior business development director responsible for driving growth in key international markets.
The details
The newly hired commercial team members will operate from locations in Glasgow, Málaga, and Manchester to build regional relationships. These hires represent a shift in the company's operational model toward decentralized business development. This structure aims to directly translate the increased aseptic manufacturing throughput into a larger footprint in the Asia-Pacific, Middle East, and Southern European markets.
Timeline
October 5, 2026: The company announced the appointment of five new commercial team members.
Market Landscape
This development follows a broader industry trend where contract manufacturers invest heavily in sterile processing capacity to capture rising global biologic drug demand. Symbiosis is now pivoting from infrastructure investment to aggressive regional sales coverage to ensure that new capacity is utilized.
Operators in the pharmaceutical supply chain should monitor how Symbiosis leverages its new capacity to compete on lead times and service availability. Firms should assess whether their current manufacturing partners are similarly positioning commercial teams to improve regional accessibility.
The takeaway
Investment in manufacturing hardware often requires a parallel investment in local commercial expertise to achieve market penetration. Owners should track whether their manufacturing partners are expanding their footprint into new regions as a leading indicator of upcoming competitive shifts.
Further reading
For more on the operational shifts in this sector, visit Healthcare.
Source note: This article includes information reported by Pharmabiz.
Live Poll
Do you believe the expansion of pharmaceutical manufacturing capacity is generally good for healthcare access?
